Rigel Pharmaceuticals Beheer
Beheer criteriumcontroles 3/4
De CEO Rigel Pharmaceuticals is Raul Rodriguez, benoemd in May2010, heeft een ambtstermijn van 14.5 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 3.44M, bestaande uit 21.2% salaris en 78.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.74% van de aandelen van het bedrijf, ter waarde $ 3.42M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.5 jaar en 6.3 jaar.
Belangrijke informatie
Raul Rodriguez
Algemeen directeur
US$3.4m
Totale compensatie
| Percentage CEO-salaris | 21.2% |
| Dienstverband CEO | 14.5yrs |
| Eigendom CEO | 0.7% |
| Management gemiddelde ambtstermijn | 3.5yrs |
| Gemiddelde ambtstermijn bestuur | 6.3yrs |
Recente managementupdates
Recent updates
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Could Be 36% Below Their Intrinsic Value Estimate
Nov 08
Rigel Pharma Remains Bullish, Growth Fueled By FDA-Approved Drugs, Strategic Partnerships
Oct 10Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Fly 31% But Investors Aren't Buying For Growth
Sep 25There's No Escaping Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Muted Revenues Despite A 29% Share Price Rise
Jul 30Rigel Pharmaceuticals: Undervalued FDA-Approved Products With Promising Cash Flow Potential
Jul 24Little Excitement Around Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Revenues As Shares Take 29% Pounding
May 01Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Mar 08Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Surges 36% Yet Its Low P/S Is No Reason For Excitement
Mar 04Rigel Pharmaceuticals: Upgrading To A 'Top Idea' Ahead Of Promising Q4/2023 Earnings Report
Feb 23Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Low P/S
Jan 15Is Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Trading At A 25% Discount?
Oct 25Rigel cutting 16% of workforce after declining to file sNDA for fostamatinib
Oct 10Rigel Pharma adds ~7% to reach over two month high
Aug 18Rigel rises 17% on strong Q2 result
Aug 03Rigel Pharmaceuticals: A Status Check
May 31Is Rigel Pharmaceuticals (NASDAQ:RIGL) A Risky Investment?
Apr 21Rigel Pharmaceuticals: Why The Stock Is On A Run
Mar 21Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$4m |
| Jun 30 2024 | n/a | n/a | -US$14m |
| Mar 31 2024 | n/a | n/a | -US$20m |
| Dec 31 2023 | US$3m | US$728k | -US$25m |
| Sep 30 2023 | n/a | n/a | -US$24m |
| Jun 30 2023 | n/a | n/a | -US$38m |
| Mar 31 2023 | n/a | n/a | -US$45m |
| Dec 31 2022 | US$3m | US$700k | -US$59m |
| Sep 30 2022 | n/a | n/a | -US$83m |
| Jun 30 2022 | n/a | n/a | -US$85m |
| Mar 31 2022 | n/a | n/a | -US$85m |
| Dec 31 2021 | US$3m | US$662k | -US$18m |
| Sep 30 2021 | n/a | n/a | -US$15m |
| Jun 30 2021 | n/a | n/a | -US$8m |
| Mar 31 2021 | n/a | n/a | -US$11m |
| Dec 31 2020 | US$3m | US$662k | -US$30m |
| Sep 30 2020 | n/a | n/a | -US$28m |
| Jun 30 2020 | n/a | n/a | -US$25m |
| Mar 31 2020 | n/a | n/a | -US$28m |
| Dec 31 2019 | US$3m | US$649k | -US$67m |
| Sep 30 2019 | n/a | n/a | -US$46m |
| Jun 30 2019 | n/a | n/a | -US$59m |
| Mar 31 2019 | n/a | n/a | -US$64m |
| Dec 31 2018 | US$4m | US$637k | -US$70m |
| Sep 30 2018 | n/a | n/a | -US$100m |
| Jun 30 2018 | n/a | n/a | -US$93m |
| Mar 31 2018 | n/a | n/a | -US$87m |
| Dec 31 2017 | US$2m | US$618k | -US$78m |
Compensatie versus markt: De totale vergoeding ($USD 3.44M ) Raul } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 2.14M ).
Compensatie versus inkomsten: De vergoeding van Raul is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Raul Rodriguez (63 yo)
14.5yrs
Tenure
US$3,440,790
Compensatie
Mr. Raul R. Rodriguez has been the Chief Executive Officer and Director of Rigel Pharmaceuticals, Inc., since November 2014 and its President since May 2010. Mr. Rodriguez served as Chief Operating Officer...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 14.5yrs | US$3.44m | 0.74% $ 3.4m | |
| Executive VP & CFO | 6.5yrs | US$1.21m | 0.069% $ 316.7k | |
| Executive VP | 1.9yrs | US$683.00k | 0.0028% $ 13.0k | |
| Executive VP & Chief Commercial Officer | 4.3yrs | US$1.34m | 0.031% $ 143.4k | |
| Senior VP of Human Resources | 2.8yrs | geen gegevens | geen gegevens | |
| Executive Vice President of Research | 8.2yrs | US$796.09k | geen gegevens | |
| Executive VP & Chief Business Officer | less than a year | geen gegevens | geen gegevens | |
| Executive VP & Chief Medical Officer | less than a year | geen gegevens | geen gegevens | |
| Vice President of Marketing | no data | geen gegevens | geen gegevens |
3.5yrs
Gemiddelde duur
61yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van RIGL wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.5 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 10yrs | US$3.44m | 0.74% $ 3.4m | |
| Independent Director | 27.7yrs | US$138.58k | 0.044% $ 201.1k | |
| Independent Director | 5.7yrs | US$145.58k | 0.043% $ 195.3k | |
| Independent Chairman of the Board | 7yrs | US$190.58k | 0.043% $ 195.3k | |
| Independent Director | 2.9yrs | US$140.58k | 0.025% $ 113.9k | |
| Independent Director | 3.5yrs | US$212.98k | 0.032% $ 146.5k |
6.3yrs
Gemiddelde duur
65yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van RIGL wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.3 jaar).